scholarly journals Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience

2020 ◽  
Vol 10 ◽  
Author(s):  
Lu Wang ◽  
Jun Zhao ◽  
Tongtong An ◽  
Yuyan Wang ◽  
Minglei Zhuo ◽  
...  
2021 ◽  
Vol 19 (2) ◽  
pp. 176-184
Author(s):  
Funda Tayfun Küpesiz ◽  
Gülen Tüysüz ◽  
Ayşe Nur Akınel ◽  
Ayşegül Tekneci ◽  
Ayşe Çiğdem Sivrice ◽  
...  

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 389-389
Author(s):  
Siwat Sakdejayont ◽  
Chirawadee Sathitruangsak ◽  
Patrapim Sunpaweravong ◽  
Arunee Dechaphunkul

389 Background: Mediastinal germ cell tumors (MGCTs) account for 20% of all mediastinal tumors. Cisplatin-based chemotherapy followed by surgical resection of residual tumor remains the standard of care. To prevent pulmonary complications secondary to extensive thoracic surgery, non-bleomycin containing regimen is generally preferred. This study aims to review clinical characteristics and outcomes of these patients. Methods: A retrospective chart review was undertaken in patients with MGCTs treated in our institution between 1993 and 2013. Results: A total of 40 patients were enrolled with a median age of 24. Only one patient is female. Stratified by histology; eight patients (20%) had pure seminoma, 25 patients (62.5%) had pure non-seminoma, four patients (10%) had mixed seminoma and non-seminoma, and three patients (7.5%) had malignant transformation (two adenocarcinoma, one sarcoma). Median tumor size was 13 centimeters. Ninety-two percent of patients received chemotherapy as a first treatment modality, whereas 8% underwent upfront surgery. All patients received cisplatin-based chemotherapy: Eighty seven percent bleomycin, etoposide and cisplatin; 13% etoposide and cisplatin. Seventy-two percent of patients completed four planned cycles of chemotherapy. Thirty-one patients were able to assess radiological response: 3.2% complete response, 58.1% partial response, 29.0% stable disease, and 9.7% progressive disease. Forty-four percent of patients achieved completely serological response with chemotherapy. Seventeen patients underwent surgical resection of residual tumor. Among these, viable tumor was seen in 35% (6 out of 17 patients). No patients complicated with clinically significant pulmonary complications after thoracic surgery. The five year overall survival (OS) of patients with seminoma was 72.9% as compared with 19.9% in those with non-seminoma (p=0.012). For those who received chemotherapy followed by surgical resection with no viable tumor or only mature teratoma detected (N=11), the five year OS was 64.9%. Conclusions: Our study confirmed the importance of multi-modality approaches with primary chemotherapy followed by surgical resection of residual tumor. Bleomycin-containing regimen can be safely used in this setting.


2008 ◽  
Vol 15 (9) ◽  
pp. 821-826 ◽  
Author(s):  
Tobias Klatte ◽  
Michela de Martino ◽  
Knut Arensmeier ◽  
Frank Reiher ◽  
Ernst P Allhoff ◽  
...  

Oncology ◽  
2013 ◽  
Vol 85 (1) ◽  
pp. 21-26 ◽  
Author(s):  
H.J. Boyle ◽  
E. Jouanneau ◽  
J.P. Droz ◽  
A. Fléchon

2017 ◽  
Vol 59 (4) ◽  
pp. 410 ◽  
Author(s):  
Sonay İncesoy-Özdemir ◽  
Ulya Ertem ◽  
Gürses Şahin ◽  
Ceyhun Bozkurt ◽  
Nazmiye Yüksek ◽  
...  

Oncotarget ◽  
2016 ◽  
Vol 7 (37) ◽  
pp. 60665-60675 ◽  
Author(s):  
Qun-Ying Yang ◽  
Cheng-Cheng Guo ◽  
Mei-Ling Deng ◽  
Jian Wang ◽  
Jing Wang ◽  
...  

2016 ◽  
Vol 27 ◽  
pp. vi304
Author(s):  
D. Chekini ◽  
A. Tryakin ◽  
M. Fedyanin ◽  
A. Bulanov ◽  
M. Ahmedova ◽  
...  

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e16544-e16544
Author(s):  
Caleb Scheckel ◽  
Heidi E. Kosiorek ◽  
Richard Butterfield ◽  
Thai Huu Ho ◽  
Talal Hilal

2018 ◽  
Vol 17 (11) ◽  
pp. e2614
Author(s):  
U. Bumbasirevic ◽  
N. Bojanic ◽  
I. Vukovic ◽  
G. Bojanic ◽  
B. Milojevic ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document